基本分析
透過季節調整季營收，判斷美股整體趨勢，但注意股價有時候領先基本面的數據，應搭配其他領先指標判斷。
基本資料
個股的基本資料，以及所屬的類股和產業。
公司介紹
業務介紹
賽瑞普塔治療公司(Sarepta Therapeutics, Inc.)是一家處於商業階段的生物製藥公司,專注於發現和開發針對罕見疾病的RNA靶向療法、基因療法和其他遺傳療法模式。該公司提供EXONDYS 51注射劑,用於治療患有確認的dystrophin基因突變且適合跳過51號外顯子的杜氏肌肉營養不良症(杜氏)患者;以及VYONDYS 53,用於治療患有確認的dystrophin基因突變且適合跳過53號外顯子的杜氏患者。該公司還在開發AMONDYS 45、SRP-5051、SRP-9001和SRP-9003等產品。該公司與多家公司和機構有合作協議,並於1980年成立,總部位於麻薩諸塞州劍橋。
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
警語
1. 資料僅供參考，不做任何獲利保證及特定股票與點位推薦建議。
2. 資料並不完整，需要完整資料請至相關網站索取。
3. 任何股市數據分析皆存在倖存者偏差。
